JMP Securities Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler maintains an Outperform rating on Aquestive Therapeutics (AQST) and raises the price target from $8 to $10.
March 15, 2024 | 10:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jason Butler maintains an Outperform rating on Aquestive Therapeutics and raises the price target from $8 to $10.
The upgrade in the price target from $8 to $10 by JMP Securities reflects a positive outlook on Aquestive Therapeutics' future performance. This endorsement by a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100